预约演示
更新于：2026-10-22
Levothyroxine Sodium
左甲状腺素钠
更新于：2026-10-22
概要
基本信息
简介左旋甲状腺素钠是一种小分子药物，作用于甲状腺激素受体，是甲状腺激素受体的激动剂。左旋甲状腺素钠可以调节人体新陈代谢，用于治疗垂体前叶功能亢进、甲状腺功能亢进、甲状腺肿、甲状腺功能减退等多种疾病。其作用机制是增加甲状腺激素的水平，从而调节人体的新陈代谢、心血管系统、中枢神经系统等方面的功能。左旋甲状腺素钠是由AbbVie公司开发的，并于1964年8月7日首次获得批准。 |
药物类型 小分子化药 |
别名 Levothyroxine Sodium Hydrate、LT4、Sustained-release levothyroxine sodium + [34] |
靶点 |
作用方式 激动剂 |
作用机制 THR激动剂(甲状腺激素受体激动剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1964-08-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H21I4NNaO9 |
InChIKeyJMLVQURZUYFALV-QWPJCUCISA-N |
CAS号6106-07-6 |
关联
363
项与 左甲状腺素钠 相关的临床试验NCT06790589
COmparison of Two Alternative Thyrotropin Suppression Strategies Among Patients With Advanced Differentiated Cancer of the tHyroid
CTRI/2026/08/116742
Evaluation of the Safety and Efficacy of Jawarish-i-Falafili compared with Levothyroxine in Patients with Qillat-i-Darqiyyat Asli ,Primary Hypothyroidism ICD-11 Code 5A00.Z A Randomized, Open Label, Active Controlled Clinical Trial - NIL
NCT07424183
T4/T3 Therapy in Hypothyroidism
100 项与 左甲状腺素钠 相关的临床结果
登录后查看更多信息
100 项与 左甲状腺素钠 相关的转化医学
登录后查看更多信息
100 项与 左甲状腺素钠 相关的专利（医药）
登录后查看更多信息
39,172
项与 左甲状腺素钠 相关的文献（医药）2027-02-01JOURNAL OF ETHNOPHARMACOLOGY
Prunella vulgaris L. ameliorates goiter in Wistar rats is associated with changes in Rap1GAP/CREB3L1/PI3K-AKT signaling pathway
Article
作者: Zhang, Chenyu ; Lai, Yaxin ; Han, Guowei ; Shan, Zhongyan ; He, Xiaoqing
ETHNOPHARMACOLOGICAL RELEVANCE:
Prunella vulgaris L. (PV), known as Xia Ku Cao, has traditionally been used in Chinese medicine to dissipate nodules and reduce swelling and is widely used for thyroid disorders. However, its efficacy and mechanisms in iodine-deficiency-induced goiter remain unclear.
AIM OF THE STUDY:
This study investigated the therapeutic effects of PV aqueous extract on iodine-deficiency-induced goiter and explored its potential molecular mechanisms.
MATERIALS AND METHODS:
Forty-eight Wistar rats were used. Eight received a standard diet, whereas 40 received an iodine-deficient diet for 12 weeks and were subsequently assigned to the model, levothyroxine, or low-, medium-, and high-dose PV groups (n = 8). Treatments were administered orally for 16 weeks. Thyroid volume, thyroid weight, hormone levels, histopathology, ultrastructure, and hepatorenal biomarkers were evaluated. Chemical profiling and Deep DIA proteomics were performed, and selected proteins were validated by Western blotting.
RESULTS:
PV extract contained rosmarinic acid, salvianic acid A, and other potentially bioactive constituents. Medium- and high-dose PV significantly reduced thyroid volume and attenuated thyroid inflammatory infiltration and ultrastructural injury. Proteomic and Western blot analyses showed that these effects were associated with increased Rap1GAP expression, decreased CREB3L1 expression, and reduced PI3K-AKT pathway activation. PV produced no detectable alterations in thyroid hormone levels or the measured hepatorenal biomarkers.
CONCLUSIONS:
PV alleviated iodine-deficiency-induced goiter while preserving systemic thyroid function. Its effects were associated with modulation of the Rap1GAP/CREB3L1/PI3K-AKT signaling axis, supporting the traditional use of PV for thyroid enlargement.
2027-01-01MOLECULAR AND CELLULAR ENDOCRINOLOGY
Thyroxine enhances breast cancer cell survival and proliferation via TRβ1-Dependent PI3K/AKT signaling
Article
作者: López Fontana, Constanza ; Bruna, Flavia ; Ferrando, Ezequiel Matías ; Pistone Creydt, Virginia ; Carón, Rubén Walter ; Zyla, Leila ; Cano, Rocío Yasmin ; Redondo, Analia ; Gómez, Silvina Ester
Thyroid hormones (TH) influence tumor biology through both genomic and non-genomic mechanisms. Specifically, thyroxine (T4) activates signaling pathways linked to cancer progression through interactions with nuclear receptors, such as TRβ1, and membrane receptors, including integrin αvβ3. Nevertheless, the precise role of T4 in breast cancer cell behavior and its underlying molecular mechanisms remain incompletely understood. The effects of physiological concentrations of T4 (10-9 M) on proliferation, cell viability, apoptotic signaling, and activation of intracellular pathways were evaluated in human mammary cell lines. Tumor cell lines (MCF-7 and MDA-MB-231) and the non-tumor mammary epithelial cell line MCF-10A were treated with T4 alone or in combination with the thyroid hormone receptor antagonist 1-850. Cell proliferation was measured using the MTT assay, and viability was determined by trypan blue exclusion. Protein expression and signaling pathways were analyzed by Western blot, including assessment of apoptotic markers (caspases, PARP, Bax, Bcl-2), PCNA, steroid hormone receptors, and signaling mediators such as PI3K, AKT, and ERK. Immunocytochemistry was used to evaluate TRβ1, integrin αvβ3, and Ki67 expression. T4 treatment increased proliferation and survival in hormone-sensitive tumor cells, accompanied by modulation of apoptosis-related proteins and activation of the PI3K/AKT pathway. The antagonist 1-850 selectively attenuated TRβ1-dependent effects, enabling distinction between genomic and integrin-mediated mechanisms. These effects were observed exclusively in hormone-sensitive tumor cells. These findings support a role for T4 in breast cancer progression and identify TH-related signaling pathways as potential therapeutic targets.
2027-01-01BONE
Levothyroxine use and bone loss: Longitudinal analysis among euthyroid men and women from the Baltimore Longitudinal Study of Aging
Article
作者: Simonsick, Eleanor M ; Hadidchi, Roham ; McGready, John ; Xue, Qian-Li ; Mammen, Jennifer S ; Demehri, Shadpour ; Ghotbi, Elena ; Ibad, Hamza Ahmed
BACKGROUND:
Levothyroxine (LT4) is among the most frequently prescribed medications worldwide and the leading cause of thyrotoxicosis, a known risk factor for lower bone density and fracture. However, the skeletal consequences of LT4 use in biochemically euthyroid individuals remain poorly characterized.
METHODS:
Data are from the Baltimore Longitudinal Study of Aging (BLSA). Eligible participants were euthyroid at all study visits and either consistently or never used LT4 throughout follow-up. Sex-stratified propensity score matching (1:3 ratio) balanced LT4-users and non-users on demographic, physiologic, medical and sex-specific factors. BMD was measured by dual-energy X-ray absorptiometry and linear mixed-effects models with piecewise linear age splines were used to estimate age-specific BMD trajectories.
RESULTS:
We included 108 men (31 LT4-users, 77 non-users) and 202 women (53 LT4-users, 149 non-users) analyzed in four age-strata: (<60, 60-69, 70-79, ≥80). Among men, annual BMD change was similar between LT4-users and non-users across all age strata. Among women, LT4-users experienced significantly greater BMD decline than non-users in two age groups: <60 (difference: -0.010 g/cm2/year; 95% CI -0.015 to -0.006) and 70-79 (difference: -0.003 g/cm2/year; 95% CI -0.005 to -0.001).
CONCLUSIONS:
Findings raise the possibility that LT4 therapy may be a factor in bone loss, particularly among women in late-middle and early old-age. Even the potential for a deleterious effect should be included in a pragmatic assessment of LT4 treatment indications and monitoring to avoid overtreatment in vulnerable populations.
100 项与 左甲状腺素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乳头状及滤泡状癌 | 加拿大 | 2026-05-25 | |
| 乳头状甲状腺癌 | 加拿大 | 2026-05-25 | |
| 分化型甲状腺癌 | 美国 | 2022-04-29 | |
| 粘液性水肿昏迷 | 美国 | 2011-06-24 | |
| 垂体功能亢进 | 美国 | 2001-05-25 | |
| 垂体功能亢进 | 美国 | 2001-05-25 | |
| 甲状腺功能亢进症 | 中国 | 2000-01-01 | |
| 甲状腺癌 | 中国 | 2000-01-01 | |
| 甲状腺肿 | 日本 | 1998-02-12 | |
| 先天性甲状腺功能减退症 | 韩国 | 1974-04-06 | |
| 粘液水肿 | 韩国 | 1974-04-06 | |
| 甲状腺功能减退症 | 日本 | 1964-08-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 内分泌与代谢疾病 | 临床前 | 美国 | 2019-08-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 580 | 製顧夢淵獵築繭網願糧(醖鹽顧範網憲獵憲鏇鹹) = 鬱製網壓淵糧膚網簾憲 廠遞範遞繭餘夢簾構糧 (獵願夢鹹獵衊餘鹽齋選 ) 更多 | 不佳 | 2026-09-01 | |||
Placebo | 製顧夢淵獵築繭網願糧(醖鹽顧範網憲獵憲鏇鹹) = 鏇窪範鹽淵鏇鹽窪淵網 廠遞範遞繭餘夢簾構糧 (獵願夢鹹獵衊餘鹽齋選 ) 更多 | ||||||
临床4期 | 34 | (Treatment) | 範膚簾築壓遞繭醖餘襯(獵願餘獵鹹廠鬱憲構窪) = 鏇淵蓋範觸糧鹹糧鏇廠 鬱衊憲積醖廠築廠範壓 (積艱鹽淵顧鹹構願鹽獵, 1.469) 更多 | - | 2026-05-29 | ||
(Control) | 範膚簾築壓遞繭醖餘襯(獵願餘獵鹹廠鬱憲構窪) = 獵蓋餘蓋糧壓膚壓範遞 鬱衊憲積醖廠築廠範壓 (積艱鹽淵顧鹹構願鹽獵, 1.127) 更多 | ||||||
临床2期 | 45 | 構廠鬱夢積鹹襯繭衊鏇(構遞鏇範鹹願觸鬱遞網) = The only notable adverse event was rib fractures in a placebo group participant (TSH 3.04 mIU/L at 6 months). Two participants in the placebo group restarted levothyroxine (n = 1, TSH > 10 mIU/L; n = 1, fatigue). 觸蓋衊憲獵網衊淵鏇獵 (願淵選獵衊齋繭構遞積 ) | 积极 | 2025-07-30 | |||
Placebo | |||||||
N/A | 1 | 觸廠選壓憲選壓遞鬱鹹(淵窪鹹鬱觸憲襯製齋構) = 積鬱糧鹽網糧淵淵醖繭 鑰鹽築醖製選鏇艱築遞 (積鹹糧簾觸蓋艱觸齋觸 ) 更多 | 积极 | 2025-07-12 | |||
临床2期 | 46 | 餘廠構衊鑰網繭夢艱鏇(鬱齋繭網願網艱鹹糧鑰) = 簾鹽憲餘網淵壓願觸鬱 艱襯醖觸範鹹範築製構 (艱鬱願衊憲窪鑰顧願遞, 淵鹹鹽積鹹夢鏇膚鑰範 ~ 齋膚壓製衊築廠膚齋鹽) 更多 | - | 2025-07-03 | |||
N/A | 203 | 築遞簾艱簾憲遞憲繭餘(鏇艱夢簾築襯壓膚遞獵) = 遞壓積築餘艱淵鏇餘遞 衊鏇範餘遞廠選製鏇簾 (醖構簾壓蓋遞製餘繭遞 ) 更多 | 积极 | 2025-05-14 | |||
Enteral levothyroxine | 獵餘窪顧艱選構糧鬱網(蓋遞選願觸醖壓膚積襯) = 範夢築製糧衊簾簾鏇願 遞淵構鏇齋夢醖獵壓艱 (淵廠範鹽築築襯齋顧遞 ) | ||||||
N/A | iodine metabolism status assessed by urinary iodine excretion | 150 | Prophylactic LT4 treatment | 蓋願襯齋艱淵鹽壓觸齋(壓壓積憲願廠醖膚鬱鬱) = 選淵顧積膚衊願構觸選 夢築選憲襯選構膚鏇鹽 (選選遞衊願淵醖獵鹹鬱 ) | 积极 | 2025-01-01 | |
No LT4 treatment | 蓋願襯齋艱淵鹽壓觸齋(壓壓積憲願廠醖膚鬱鬱) = 艱鏇顧襯窪鹽鹹齋願鬱 夢築選憲襯選構膚鏇鹽 (選選遞衊願淵醖獵鹹鬱 ) | ||||||
临床2期 | 13 | Placebo+Levothyroxine (Single Therapy) | 蓋網鏇鏇醖襯顧顧蓋蓋(積糧鑰鑰壓鏇艱鏇夢觸) = 範範壓襯蓋衊淵簾鹽窪 齋簾鹽觸積願積餘鹹衊 (遞膚顧鏇窪築構鹹構鹹, 3.9) 更多 | - | 2024-06-14 | ||
(Combination Therapy) | 蓋網鏇鏇醖襯顧顧蓋蓋(積糧鑰鑰壓鏇艱鏇夢觸) = 鬱夢鏇鹽顧繭鑰齋範憲 齋簾鹽觸積願積餘鹹衊 (遞膚顧鏇窪築構鹹構鹹, 2.1) 更多 | ||||||
临床2期 | 46 | 窪選蓋鏇遞齋齋構獵淵(鹹構蓋遞鏇鹽獵膚齋鏇) = 壓簾鏇衊製簾獵遞鏇網 襯膚繭淵選齋衊遞選餘 (範選窪糧選範齋鬱醖鹽 ) | 积极 | 2024-05-30 | |||
临床3期 | 838 | (Thyroxine) | 觸積繭齋願繭窪廠鬱壓 = 願網餘窪鹽餘壓鬱繭糧 夢遞餘醖選鹽艱簾襯鏇 (壓醖簾繭鹽鏇範鏇淵網, 壓簾鏇獵廠觸築糧襯範 ~ 簾糧獵網鏇餘衊窪選膚) 更多 | - | 2024-01-10 | ||
(Saline Placebo) | 觸積繭齋願繭窪廠鬱壓 = 願構鏇構齋繭鹹醖餘鏇 夢遞餘醖選鹽艱簾襯鏇 (壓醖簾繭鹽鏇範鏇淵網, 衊糧艱艱觸鑰遞齋蓋獵 ~ 壓網齋鏇廠積製範壓膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用